IP Library › Granted Patent US 10,583,114
Granted Patent B2
US 10,583,114 · App. 15/029,384 · Granted Mar 10, 2020

Compositions comprising urolithins and uses thereof for the stimulation of insulin secretion

Inventors: Gerard Cros (Montpellier, FR); Alan Crozier (Scotland, GB); Margherita Dall'asta (Parma, IT); Daniele Del Rio (Parma, IT); Richard Magous (Lunel, FR); Catherine Oiry (Pignan, FR)
Assignees: Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; University of Parma; Ecole Nationale Superieure de Chimie; Centre National de la Recherche Scientifique; Universite de Montpellier
A61K31/37A61K31/255A61K38/26A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,583,114
App. No.
15/029,384
Granted
Mar 10, 2020
Kind
B2
Abstract

The present invention relates to a composition comprising urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, for the stimulation of insulin secretion, and to the use of a compound chosen among urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, intended for the stimulation of insulin secretion. The present invention also relates to a composition comprising an effective amount of urolithin B, urolithin C, urolithin D, or a combination thereof, for the treatment or the prevention of diabetes mellitus, and in particular for the treatment or the prevention of type 2 diabetes, and to the use of a compound chosen among urolithin B, urolithin C, urolithin D, and a combination thereof, intended for the treatment or the prevention of diabetes mellitus, and in particular of type 2 diabetes.

Claims (3)

1. A method for treating type 2 diabetes comprising administering, to a mammal in need thereof, urolithin C, and a compound able to stimulate insulin secretion, wherein said compound able to stimulate insulin secretion is selected from the group of: sulfonylureas, GLP-1 analogs, and DPP4 inhibitors.

2. The method according to claim 1 , wherein the compound able to stimulate insulin secretion is a sulfonylurea that is glibenclamide.

3. The method according to claim 1 , wherein the compound able to stimulate insulin secretion is a GLP-1 analog that is exenatide.

Assignments (2)
MERGER Recorded Jun 14, 2021
From: ECOLE NATIONALE SUPERIEURE DE CHIMIE
To: ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIER
Reel/Frame 056531/0193 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2020
From: CROS, GÉRARD; CROZIER, ALAN; DALL'ASTA, MARGHERITA; DEL RIO, DANIELE; MAGOUS, RICHARD; OIRY, CATHERINE
To: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS); UNIVERSITE DE MONTPELLIER; UNIVERSITY OF PARMA; ECOLE NATIONALE SUPERIEURE DE CHIMIE
Reel/Frame 051598/0654 →
Priority Claims (1)
EP 13306415 · Oct 15, 2013 · regional
Continuity (1)
Related Publication 20160279097A1 · Sep 29, 2016